Jalil Anwar, MD
Pulmonary Disease · Huntington, NYNPI 1053405084
Payments from drug & device makers
Across 528 payments — averaging $21.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- AstraZeneca$2K
- GSK$1K
- Harmony Biosciences LLC$1K
- Actelion Pharmaceuticals US, Inc.$1K
- Grifols USA, LLC$724
- plus $4K from 30 others
What the payments were for
- Food & beverage$11,07696%
- Education$4984%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 83 | $1,828 |
| AstraZeneca | 76 | $1,744 |
| GSK | 69 | $1,279 |
| Harmony Biosciences LLC | 65 | $1,233 |
| Actelion Pharmaceuticals US, Inc. | 37 | $1,068 |
| Grifols USA, LLC | 32 | $724 |
| Jazz Pharmaceuticals Inc. | 19 | $546 |
| Philips North America LLC | 21 | $425 |
| Mylan Specialty L.p. | 23 | $424 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $306 |
| Inspire Medical Systems, Inc. | 7 | $269 |
| Merck | 13 | $209 |
| Verona Pharma, Inc. | 8 | $193 |
| Baxter Healthcare | 7 | $151 |
| Insmed, Inc. | 5 | $129 |
| Mallinckrodt Hospital Products Inc. | 4 | $110 |
| Novo Nordisk | 1 | $98 |
| Electromed, Inc. | 6 | $94 |
| Viatris Specialty LLC | 5 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $87 |
| Advanced Respiratory, Inc | 5 | $79 |
| Amgen | 3 | $73 |
| Bayer | 2 | $61 |
| Pfizer | 2 | $50 |
| Atricure, Inc. | 1 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Sanofi | 2 | $37 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Circassia Inc. | 2 | $28 |
| Lilly USA, LLC | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| 3b Medical, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$372
- Inspire$137
- OFEV$124
- BREZTRI$120
- Prolastin-C Liquid$112
How this compares
$11,574 in reported general payments places this provider in the 80th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 298 | $317,833 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $57,993 |
| EliquisApixaban | 53 | $51,571 |
| Spiriva RespimatTiotropium Bromide | 46 | $51,099 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $46,726 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $28,542 |
| Spiriva HandihalerTiotropium Bromide | 19 | $27,430 |
| JanuviaSitagliptin Phosphate | 16 | $24,089 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $21,592 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $19,777 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $12,508 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 66 | $11,827 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $11,169 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 44 | $8,969 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 209 | $8,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,279 | $432,697461 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,744 | $66,50396 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $1,828 | $63,60861 claims |
| PfizerEliquis | $50 | $51,57153 claims |
| MerckJanuvia | $209 | $24,08916 claims |
| Lilly USA, LLCHumalog | $25 | $7,81713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Huntington
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.